Use in Special Populations
Pregnant Women
Animal studies indicate that this product may have potential effects on the fetus. Pregnant women should use it only after carefully weighing the benefits and risks. If you are pregnant or planning a pregnancy, please inform your doctor promptly to discuss the optimal treatment plan.
Breastfeeding Women
Animal studies show that this product may be excreted in breast milk. Breastfeeding women should use it with caution. If treatment is necessary, breastfeeding should be discontinued. Please consult your doctor for details.
Adolescents and Children
There is currently insufficient evidence regarding the safety and efficacy of this product in pediatric patients. Use in children under 12 years of age is not recommended.
Elderly Patients
Elderly patients may be more sensitive to the drug and are prone to liver injury. Use with caution, and if necessary, adjust the dosage under medical supervision.
Patients with Hepatic Impairment
Avatrombopag ethanolamine tablets have hepatotoxicity. Use with caution in patients with liver injury; if necessary, start with a low dose. Please consult your doctor for details.
Patients with Renal Impairment
Use with caution in patients with renal injury. If treatment is necessary, closely monitor changes in renal function indicators. Please consult your doctor for details.
Patients at Thromboembolism Risk
Patients at risk of thromboembolism, such as those of advanced age, with malignant tumors, prolonged bed rest, receiving contraception and hormone replacement therapy, recent surgery or trauma, obesity, or smoking, should also use this product with caution.
Drug Interactions of Avatrombopag Ethanolamine Tablets
Interaction with Elbasvir and Grazoprevir
Avatrombopag ethanolamine tablets may interact with elbasvir and grazoprevir tablets, affecting drug absorption or increasing the incidence of side effects; therefore, concomitant use is not recommended.
Interactions with Other Drugs
When avatrombopag ethanolamine tablets are used with the following drugs, attention should be paid to adjusting the drug dosage or frequency of administration. Please consult your doctor for details:
Chelation with Polyvalent Cations
This product can chelate with polyvalent cations such as iron, calcium, magnesium, aluminum, selenium, and zinc. Therefore, this product should be administered at least 2 hours before or 4 hours after antacids, dairy products, and other drugs containing polyvalent cations (e.g., mineral supplements) to avoid a significant reduction in absorption due to chelation.
Concomitant Use with Lipid-Regulating Drugs
Concomitant use with lipid-regulating drugs (including atorvastatin, fluvastatin, lovastatin, pitavastatin, and simvastatin) may increase the risk of side effects. Therefore, the dose of these statins should be reduced, and their side effects should be carefully monitored.
Concomitant Use with OATP1B1 and BCRP Substrates
Use with caution when co-administering this product with OATP1B1 and BCRP substrates (e.g., topotecan and methotrexate).
Concomitant Use with Cyclosporine
Concomitant use with cyclosporine may reduce the absorption of avatrombopag ethanolamine tablets. If co-administration is necessary, monitor platelet counts at least once weekly for 2–3 weeks, and adjust the dosage of this product based on platelet counts.
Concomitant Use with Lopinavir and Ritonavir
Concomitant use with lopinavir and ritonavir may reduce the plasma concentration of avatrombopag ethanolamine tablets. Use with caution; if co-administration is necessary, closely monitor platelet counts and adjust the dosage accordingly.
Concomitant Use with CYP Inhibitors or Inducers
Concomitant use with CYP inhibitors or inducers (e.g., fluvoxamine and rifampin) may increase or decrease the plasma concentration of avatrombopag ethanolamine tablets. Use with caution; if co-administration is necessary, closely monitor platelet counts and adjust the dosage in a timely manner.
